Century Therapeutics (IPSC)
NASDAQ:IPSC
Top Page
Century Therapeutics
(NASDAQ:IPSC)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.00
▼(-11.50% Downside)
Action:ReiteratedDate:03/27/26
The score is held down primarily by heavy ongoing cash burn and uneven revenue visibility despite improved net losses and a manageable leverage profile. Technicals are mixed with weak near-term trend but some longer-term support. Corporate events are a positive offset due to strengthened liquidity and listing stability, while valuation remains constrained by unprofitability and no dividend.
Positive Factors
Platform and pipeline progress
Century’s Allo‑Evasion platform and multiple programs (CNTY‑813, CNTY‑308, CNTY‑101 activity) create a durable competitive position in immune‑evasive allogeneic cell therapy. Advancing several IND‑enabling and early clinical programs in parallel reduces single‑asset binary risk and increases optionality for partnerships or value realization over the next 2–3 years.
Negative Factors
Sustained high cash burn
Persistently large negative operating and free cash flow indicates the company will remain dependent on external financing until product revenues or significant milestone payments arise. High burn increases dilution risk, constrains discretionary investment, and requires management to continually access capital markets absent material revenue inflection.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform and pipeline progress
Century’s Allo‑Evasion platform and multiple programs (CNTY‑813, CNTY‑308, CNTY‑101 activity) create a durable competitive position in immune‑evasive allogeneic cell therapy. Advancing several IND‑enabling and early clinical programs in parallel reduces single‑asset binary risk and increases optionality for partnerships or value realization over the next 2–3 years.
Read all positive factors
Century Therapeutics (IPSC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$406.17M
Dividend YieldN/A
Average Volume (3M)1.46M
Price to Earnings (P/E)―
Beta (1Y)2.04
Revenue Growth4121.12%
EPS Growth83.30%
CountryUS
Employees140
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.25
Shares Outstanding179,722,750
10 Day Avg. Volume1,934,156
30 Day Avg. Volume1,458,432
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.54
Price to Sales (P/S)0.79
P/FCF Ratio-0.82
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue1.62
Enterprise Value/Gross Profit1.79
Enterprise Value/Ebitda-91.47
Forecast
1Y Price Target
$5.30Price Target Upside134.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.58
Revenue Forecast (FY)N/A
Century Therapeutics Business Overview & Revenue Model
Company Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced plurip...
How the Company Makes Money
Century Therapeutics does not primarily generate revenue from product sales because its therapeutic candidates are in clinical development and are not commercialized. The company’s revenue, when reported, has primarily come from collaboration and ...
Century Therapeutics Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 109.16M | 6.59M | 2.23M | 5.20M | 0.00 |
| Gross Profit | 96.06M | 6.59M | 2.23M | 5.20M | -4.58M |
| EBITDA | -1.94M | -111.47M | -121.21M | -121.20M | -89.92M |
| Net Income | -9.58M | -126.57M | -136.67M | -130.93M | -95.82M |
Balance Sheet | |||||
| Total Assets | 223.70M | 353.22M | 360.69M | 486.54M | 437.38M |
| Cash, Cash Equivalents and Short-Term Investments | 117.11M | 189.29M | 172.74M | 315.50M | 222.88M |
| Total Debt | 43.56M | 53.83M | 48.17M | 49.41M | 25.12M |
| Total Liabilities | 64.77M | 191.85M | 175.94M | 183.81M | 41.14M |
| Stockholders Equity | 158.94M | 161.36M | 184.75M | 302.74M | 396.24M |
Cash Flow | |||||
| Free Cash Flow | -104.72M | -110.29M | -102.08M | -16.55M | -133.97M |
| Operating Cash Flow | -103.88M | -110.14M | -88.35M | 14.05M | -89.00M |
| Investing Cash Flow | 107.50M | 47.48M | 61.13M | -13.13M | -298.34M |
| Financing Cash Flow | 173.00K | 74.56M | -9.72M | 27.16M | 417.77M |
Century Therapeutics Technical Analysis
Positive
2.26
Price Trends
2.20
Negative
1.58
Positive
1.06
Positive
Market Momentum
-0.02
Positive
48.56
Neutral
40.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IPSC, the sentiment is Positive. The current price of 2.26 is below the 20-day moving average (MA) of 2.34, above the 50-day MA of 2.20, and above the 200-day MA of 1.06, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 48.56 is Neutral, neither overbought nor oversold. The STOCH value of 40.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IPSC.
Century Therapeutics Risk Analysis
Century Therapeutics disclosed 90 risk factors in its most recent earnings report. Century Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Century Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $406.17M | -1.12 | -4.88% | ― | 4121.12% | 83.30% | |
46 Neutral | $22.38M | -0.45 | -310.89% | ― | ― | 49.43% | |
46 Neutral | $19.81M | ― | -1041.79% | ― | ― | 1.18% | |
44 Neutral | $29.51M | -0.39 | 71.83% | ― | -66.96% | 71.83% | |
42 Neutral | $36.71M | -1.25 | -208.66% | ― | 11.11% | 20.65% | |
40 Underperform | $10.09M | -3,346.34 | -526.36% | ― | ― | -2.46% |
* Healthcare Sector Average
IPSC
Century Therapeutics
2.26
1.87
480.98%
TPST
Tempest Therapeutics
1.56
-4.95
-76.04%
ATNM
Actinium Pharmaceuticals
1.17
-0.04
-3.31%
BTAI
Bioxcel Therapeutics
1.09
-0.38
-25.85%
LTRN
Lantern Pharma
1.76
-0.82
-31.78%
CALC
CalciMedica
0.64
-1.08
-62.73%
Century Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Century Therapeutics Updates ATM Program to Enhance Liquidity
Positive
Mar 26, 2026
On July 10, 2025, Century Therapeutics, Inc. filed a new shelf registration statement that became effective on January 9, 2026, replacing its prior shelf registration and enabling continued access to the capital markets. In connection with this, o...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Century Therapeutics Reports 2025 Results and Pipeline Progress
Positive
Mar 12, 2026
On March 12, 2026, Century Therapeutics reported its full-year 2025 results, highlighting progress on CNTY-813, a beta islet replacement therapy for type 1 diabetes, and CNTY-308, a CD19-targeted CAR-iT cell candidate for B-cell-mediated diseases....
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
Century Therapeutics Regains Nasdaq Compliance, Halts Reverse Split
Positive
Jan 23, 2026
On January 22, 2026, Century Therapeutics, Inc. held a virtual special meeting of stockholders at which shareholders approved an amendment to the company’s certificate of incorporation authorizing a potential reverse stock split of its commo...
Business Operations and StrategyProduct-Related Announcements
Century Therapeutics Highlights Progress in Immune-Evasive Cell Therapies
Positive
Jan 12, 2026
On January 12, 2026, Century Therapeutics updated an investor slide presentation detailing progress across its cell therapy pipeline and plans to unlock the value of its programs in Type 1 diabetes and autoimmune disease. The company highlighted t...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Century Therapeutics Announces Oversubscribed $135 Million Financing
Positive
Jan 8, 2026
On January 7, 2026, Century Therapeutics entered into a securities purchase agreement with institutional investors for an oversubscribed private placement expected to close on January 9, 2026, raising approximately $135 million in gross proceeds t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.